189 related articles for article (PubMed ID: 1322401)
21. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
[TBL] [Abstract][Full Text] [Related]
22. The endothelial cell tissue plasminogen activator receptor. Specific interaction with plasminogen.
Hajjar KA
J Biol Chem; 1991 Nov; 266(32):21962-70. PubMed ID: 1657983
[TBL] [Abstract][Full Text] [Related]
23. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells.
Sakata Y; Okada M; Noro A; Matsuda M
J Biol Chem; 1988 Feb; 263(4):1960-9. PubMed ID: 3123483
[TBL] [Abstract][Full Text] [Related]
24. Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor 1 complexes in Hep G2 cells.
Underhill DM; Owensby DA; Morton PA; Schwartz AL
Blood; 1992 Dec; 80(11):2746-54. PubMed ID: 1333299
[TBL] [Abstract][Full Text] [Related]
25. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
Sitter T; Toet K; Quax P; Kooistra T
Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
[TBL] [Abstract][Full Text] [Related]
26. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.
Otter M; Kuiper J; Bos R; Rijken DC; van Berkel TJ
Biochem J; 1992 Jun; 284 ( Pt 2)(Pt 2):545-50. PubMed ID: 1318035
[TBL] [Abstract][Full Text] [Related]
28. Studies on the effect of fucosylated and non-fucosylated finger/growth-factor constructs on the clearance of tissue-type plasminogen activator mediated by the low-density-lipoprotein-receptor-related protein.
Camani C; Gavin O; Bertossa C; Samatani E; Kruithof EK
Eur J Biochem; 1998 Feb; 251(3):804-11. PubMed ID: 9490055
[TBL] [Abstract][Full Text] [Related]
29. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.
Orth K; Willnow T; Herz J; Gething MJ; Sambrook J
J Biol Chem; 1994 Aug; 269(33):21117-22. PubMed ID: 8063731
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the binding of plasminogen activators to plasma membranes from human liver.
Nguyen G; Self SJ; Camani C; Kruithof EK
Biochem J; 1992 Nov; 287 ( Pt 3)(Pt 3):911-5. PubMed ID: 1445249
[TBL] [Abstract][Full Text] [Related]
31. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
[TBL] [Abstract][Full Text] [Related]
33. Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells.
Rosenfeld L; Kuo A; Hirsh J; Klugherz B; Gardell SJ; Cines DB; Barnathan ES
Blood; 1992 Sep; 80(6):1486-95. PubMed ID: 1520875
[TBL] [Abstract][Full Text] [Related]
34. Urokinase binding and receptor identification in cultured endothelial cells.
Haddock RC; Spell ML; Baker CD; Grammer JR; Parks JM; Speidel M; Booyse FM
J Biol Chem; 1991 Nov; 266(32):21466-73. PubMed ID: 1657968
[TBL] [Abstract][Full Text] [Related]
35. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor.
Gaussem P; Grailhe P; Anglés-Cano E
J Biol Chem; 1993 Jun; 268(16):12150-5. PubMed ID: 8505335
[TBL] [Abstract][Full Text] [Related]
36. Binding of tissue plasminogen activator to human monocytes and monocytoid cells.
Felez J; Chanquia CJ; Levin EG; Miles LA; Plow EF
Blood; 1991 Nov; 78(9):2318-27. PubMed ID: 1932747
[TBL] [Abstract][Full Text] [Related]
37. Determinants of binding and internalization of tissue-type plasminogen activator by human vascular smooth muscle and endothelial cells.
Grobmyer SR; Kuo A; Orishimo M; Okada SS; Cines DB; Barnathan ES
J Biol Chem; 1993 Jun; 268(18):13291-300. PubMed ID: 7685759
[TBL] [Abstract][Full Text] [Related]
38. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
40. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
